This inventor holds 2 USPTO granted patents and 6 published patent applications. Top assignee: Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Innovations by Haiwen Hu in Pharmaceutical Development
Introduction
Haiwen Hu is a notable inventor based in Zhejiang, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of GLP-1 receptor agonists. With a total of 2 patents, his work focuses on innovative solutions for treating metabolic disorders, including type 2 diabetes.
Latest Patents
Haiwen Hu's latest patents include two key inventions. The first is a crystalline form A of a GLP-1 receptor agonist, specifically designed for the treatment of various conditions and metabolic disorders. This invention relates to a crystal form A of (S)-2-(3S,8S)-3-(4-(3,4-dichlorobenzyloxy)phenyl-7-((S)-1-phenylpropyl)-2,3,6,7,8,9-hexahydro-[1,4]-dioxino[2,3-g]isoquinolin-8-ylformylamino)-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propionic acid ('OAD2'), along with methods of preparation. The second patent involves pharmaceutically acceptable acid salts of the free base of the GLP-1 receptor agonist, which may also be beneficial in treating metabolic disorders.
Career Highlights
Haiwen Hu is currently employed at Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. His work at this company has allowed him to focus on innovative pharmaceutical research and development. His contributions have been instrumental in advancing treatments for diabetes and other metabolic conditions.
Collaborations
Throughout his career, Haiwen Hu has collaborated with several professionals in the field, including Li Fang and Fan Hu. These collaborations have enhanced his research and contributed to the successful development of his patented inventions.
Conclusion
Haiwen Hu's innovative work in the pharmaceutical industry showcases his commitment to improving treatments for metabolic disorders. His patents reflect significant advancements in the field, particularly in the development of GLP-1 receptor agonists.